Evotec : increases its profitability guidance for 2018
December 19, 2018 at 07:50 am EST
Share
DGAP-Ad-hoc: Evotec AG / Key word(s): Change in Forecast
Evotec AG increases its profitability guidance for 2018
19-Dec-2018 / 13:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it increases its profitability guidance for the current year after completing its latest financial evaluation.
The Company now expects adjusted Group EBITDA* to increase by more than 45% (previously: Improve by approx. 30%) in 2018 compared to last year (2017: EUR 58.4 m). This mainly results from Evotec's strong business performance leading to increased margin contribution, important scientific milestone achievements in the fourth quarter of 2018 as well as increased other operating income due to e.g. research & development ("R&D") tax credits in the second half of 2018.
All other elements of the Company's financial guidance are confirmed.
*(EBITDA excludes contingent considerations, income from bargain purchase and impairments on goodwill, other intangible and tangible assets as well as the total non-operating result)
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com
19-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone:
+49 (0)40 560 81-0
Fax:
+49 (0)40 560 81-222
E-mail:
info@evotec.com
Internet:
www.evotec.com
ISIN:
DE0005664809
WKN:
566480
Indices:
MDAX, TecDAX
Listed:
Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
EVOTEC SE 
